glp-1 employer coverage news october 2025 Debate Comes Down to a 'Prisoner's Dilemma,' Lilly SVP Says Perspectives from employers on the
Description
6 (2007): 21312157, 10.1053/j.gastro.2007.03.054
If you have questions, write them down
The ongoing multidistrict litigation (MDL) against pharmaceutical giants Novo Nordisk and Eli Lilly concerning GLP-1 drugs, including Ozempic, Wegovy, Trulicity, and Mounjaro, continues to develop as plaintiffs claim these medications have caused serious gastrointestinal injuries
The region benefits from strong GLP-1 penetration in the United States, where prescriptions exceeded 7% of all dispensed prescriptions by December 2025
In fact, clinical trials show that these medications work best in conjunction with education on eating and exercise
